Full View

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities

C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - academic.oup.com
The multitargeted tyrosine‐kinase inhibitor sunitinib has emerged as one of the standards of
care for good‐and intermediate‐risk metastatic renal cell carcinoma. Although generally …
被引用次数：103 相关文章
[PDF] wiley.com

[PDF][PDF] Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities

C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - Wiley Online Library
The multitargeted tyrosine‐kinase inhibitor sunitinib has emerged as one of the standards of
care for good‐and intermediate‐risk metastatic renal cell carcinoma. Although generally …

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities

C Kollmannsberger, G Bjarnason, P Burnett, P Creel… - Oncologist, 2011 - hero.epa.gov
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of
care for good-and intermediate-risk metastatic renal cell carcinoma. Although generally …

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities

C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - pubmed.ncbi.nlm.nih.gov
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of
care for good-and intermediate-risk metastatic renal cell carcinoma. Although generally …
[HTML] nih.gov

[HTML][HTML] Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities

C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - ncbi.nlm.nih.gov
CHRISTIAN KOLLMANNSBERGER, a GEORG BJARNASON, b PATRICK BURNETT, c
PATRICIA CREEL, d MELLAR DAVIS, e NANCY DAWSON, f DARREN FELDMAN, g …
[PDF] researchgate.net

[PDF][PDF] Academia–PharmaIntersect: Genitourinary Cancer: Renal, Bladder, and Testicular

C KOLLMANNSBERGER, G BJARNASON… - researchgate.net
CHRISTIAN KOLLMANNSBERGER, a GEORG BJARNASON, b PATRICK BURNETT, c
PATRICIA CREEL, d MELLAR DAVIS, e NANCY DAWSON, f DARREN FELDMAN, g …

Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities

C Kollmannsberger, G Bjarnason, P Burnett, P Creel… - The Oncologist, 2011 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The multitargeted tyrosine-kinase inhibitor
sunitinib has emerged as one of the standards of care for good-and intermediate-risk …
[PDF] academia.edu

[PDF][PDF] Academia–PharmaIntersect: Genitourinary Cancer: Renal, Bladder, and Testicular

C KOLLMANNSBERGER, G BJARNASON… - academia.edu
CHRISTIAN KOLLMANNSBERGER, a GEORG BJARNASON, b PATRICK BURNETT, c
PATRICIA CREEL, d MELLAR DAVIS, e NANCY DAWSON, f DARREN FELDMAN, g …

Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities.

C Kollmannsberger, G Bjarnason, P Burnett… - …, 2011 - search.ebscohost.com
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of
care for good and intermediate-risk metastatic renal cell carcinoma. Although generally …

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - europepmc.org
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of
care for good-and intermediate-risk metastatic renal cell carcinoma. Although generally …